Vir Biotechnology Q4 revenue beats estimates

Vir Biotechnology

23/02/2026 22:23

Overview

Biopharmaceutical firm's Q4 revenue beat analyst expectations, driven by Norgine license revenue

Company reported a net loss for Q4, decreased compared to last year

Company announced collaboration with Astellas for prostate cancer treatment development

Outlook

Vir expects cash reserves to fund operations into Q2 2028

Result Drivers

NORGINE LICENSE REVENUE - Q4 revenue increase driven by $64.3 mln license revenue from Norgine agreement for hepatitis delta treatment

COST SAVINGS - Decrease in R&D and SG&A expenses due to cost savings from restructuring initiatives

Company press release: ID:nBwbtQvVSa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$64.10 mln
$23.18 mln (6 Analysts)
Q4 EPS
-$0.31
Q4 Net Income
-$42.9 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Vir Biotechnology Inc is $14.50, about 95.2% above its February 23 closing price of $7.43

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)